Is Diabetic Skeletal Fragility Associated with Microvascular Complications in Bone?
- 21 January 2017
- journal article
- review article
- Published by Springer Nature in Current Osteoporosis Reports
- Vol. 15 (1) , 1-8
Abstract
The objective of this literature review is to determine whether there are indications that microvascular complications occur in diabetic bone. Evidence definitively linking diabetic skeletal fragility with microvascular complications in bone remains elusive. Circumstantial evidence, some recent and some lost to time, suggests that atherosclerotic vascular diseases such as peripheral arterial disease cause poor blood perfusion of bone and subsequent hypoxia and contribute to low bone density and high cortical porosity, patterns similar to some recently observed in diabetic subjects. Evidence also exists to suggest that potentially anti-angiogenic conditions, such as impaired vascular endothelial growth factor (VEGF) signaling, predominate in diabetic bone. Microvascular complications may contribute, in part, to diabetic skeletal fragility but data supporting this interpretation are primarily circumstantial at this time. This review highlights gaps in our knowledge and hopefully spurs further discussions and research on this topic.Keywords
This publication has 108 references indexed in Scilit:
- Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studiesEuropean Journal of Epidemiology, 2012
- Association of BMD and FRAX Score With Risk of Fracture in Older Adults With Type 2 DiabetesJAMA, 2011
- The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissuesProceedings of the National Academy of Sciences of the United States of America, 2009
- VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesisProceedings of the National Academy of Sciences, 2009
- Stabilization of HIF-1α is critical to improve wound healing in diabetic miceProceedings of the National Academy of Sciences, 2008
- Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7Proceedings of the National Academy of Sciences, 2008
- VEGF-C, a Lymphatic Growth Factor, Is a RANKL Target Gene in Osteoclasts That Enhances Osteoclastic Bone Resorption through an Autocrine MechanismJournal of Biological Chemistry, 2008
- A post‐transcriptional pathway represses monocyte VEGF‐A expression and angiogenic activityThe EMBO Journal, 2007
- Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathwaysBone, 2007
- The biology of VEGF and its receptorsNature Medicine, 2003